PLK1 and urothelial carcinoma: PLK1 expression effectively predicted the outcomes in urothelial carcinoma patients in the IMvigor210 cohort after anti-PD-L1 therapy, and thus warrants further exploration as a predictive biomarker of immunotherapy response.